# Eli Lilly and Company (LLY) — Q3-2023 Earnings Results

**Report date:** 2023-11-02 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q3-2023

## Post-Earnings Brief

### Headline

Eli Lilly Beats on EPS, Stock Up 4.66%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.10 | N/A | +195.24% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on delivering innovative treatments.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Eli Lilly's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 4.66%. The company did not disclose revenue figures or future guidance, leaving some uncertainty. Investors may view the EPS beat as a sign of strong operational performance, but the lack of revenue data could raise questions about overall growth.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q3-2023_